107 related articles for article (PubMed ID: 11170921)
1. Thermophilic multidrug-resistant Campylobacter fetus infection with hypersplenism and histiocytic phagocytosis in a patient with acquired immunodeficiency syndrome.
Anstead G; Jorgensen J; Craig F; Blaser M; Patterson T
Clin Infect Dis; 2001 Jan; 32(2):295-6. PubMed ID: 11170921
[TBL] [Abstract][Full Text] [Related]
2. Jejunal infection with Campylobacter.
Ward TT; Klein K; Borthistle BK
Arch Intern Med; 1984 May; 144(5):1072-4. PubMed ID: 6712398
[TBL] [Abstract][Full Text] [Related]
3. [Chronic diarrhea caused by Campylobacter jejuni in a patient with AIDS].
Darbas H; Pelous C; Jean A; Boyer G; Jean-Pierre H; Donadio D; Navarro M
Pathol Biol (Paris); 1988 Sep; 36(7):888-90. PubMed ID: 3059270
[TBL] [Abstract][Full Text] [Related]
4. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
5. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
6. [Four cases of infection by Campylobacter fetus ssp. fetus].
Yamazaki E; Kitano A; Mizuoka K
Rinsho Byori; 1986 Jun; 34(6):716-22. PubMed ID: 3747211
[No Abstract] [Full Text] [Related]
7. Campylobacter laridis bacteraemia in an AIDS patient.
Dionisio D; Milo D; Mazzotta D; Pecile P
Boll Ist Sieroter Milan; 1989; 68(2):199-200. PubMed ID: 2491307
[TBL] [Abstract][Full Text] [Related]
8. [A case of septicemia by Campylobacter fetus subsp. fetus].
Nagoya H; Sasaki H; Enomoto S; Iwasaki Y; Nara Y
Rinsho Byori; 1984 Feb; 32(2):191-6. PubMed ID: 6737735
[No Abstract] [Full Text] [Related]
9. Control of glycopeptide-resistant enterococci in an oncology unit.
Bradley SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):203S-212S; discussion 224S-228S. PubMed ID: 11001327
[TBL] [Abstract][Full Text] [Related]
10. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study.
Helms M; Simonsen J; Olsen KE; Mølbak K
J Infect Dis; 2005 Apr; 191(7):1050-5. PubMed ID: 15747238
[TBL] [Abstract][Full Text] [Related]
11. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
12. [Campylobacter fetus bacteremia and cellulitis complicating a venous access port infection in an HIV infected patient].
Rapp C; Imbert P; Fabre R; Cavallo JD; Debord T
Med Mal Infect; 2007 May; 37(5):284-6. PubMed ID: 17446026
[TBL] [Abstract][Full Text] [Related]
13. A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis.
Ozkiriş A; Evereklioglu C; Akgün H; Eşel D; Caner F; Erkiliç K
Exp Eye Res; 2005 Mar; 80(3):361-7. PubMed ID: 15721618
[TBL] [Abstract][Full Text] [Related]
14. Campylobacter jejuni diarrhea in Nebraska.
Kruger RL
Nebr Med J; 1981 May; 66(5):113-4. PubMed ID: 7231599
[No Abstract] [Full Text] [Related]
15. Short-term and medium-term clinical outcomes of quinolone-resistant Campylobacter infection.
Evans MR; Northey G; Sarvotham TS; Rigby CJ; Hopkins AL; Thomas DR
Clin Infect Dis; 2009 Jun; 48(11):1500-6. PubMed ID: 19400688
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Prakash SK; Arora V; Prashad R; Sharma VK
J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
Hou F; Li J; Gao L; Chen Y
Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
[TBL] [Abstract][Full Text] [Related]
18. Persistence of multiply antibiotic-resistant Campylobacter jejuni in a patient with the acquired immune deficiency syndrome.
Dworkin B; Wormser GP; Abdoo RA; Cabello F; Aguero ME; Sivak SL
Am J Med; 1986 May; 80(5):965-70. PubMed ID: 3706381
[TBL] [Abstract][Full Text] [Related]
19. [Campylobacter infections].
Sagara H; Matsubara Y
Nihon Rinsho; 1986 Aug; 44(8):1912-20. PubMed ID: 3537380
[No Abstract] [Full Text] [Related]
20. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
Thomson KS; Black J; Moland ES; Reuben J; Wiles T; Brasso W
Int J Antimicrob Agents; 2008 Jan; 31(1):83-5. PubMed ID: 17996426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
